SE0401465D0 - New substituted piperdines as modulators of dopamine neurotransmission - Google Patents

New substituted piperdines as modulators of dopamine neurotransmission

Info

Publication number
SE0401465D0
SE0401465D0 SE0401465A SE0401465A SE0401465D0 SE 0401465 D0 SE0401465 D0 SE 0401465D0 SE 0401465 A SE0401465 A SE 0401465A SE 0401465 A SE0401465 A SE 0401465A SE 0401465 D0 SE0401465 D0 SE 0401465D0
Authority
SE
Sweden
Prior art keywords
piperdines
modulators
new substituted
dopamine neurotransmission
neurotransmission
Prior art date
Application number
SE0401465A
Other languages
English (en)
Inventor
Clas Sonesson
Lars Swanson
Nicholas Waters
Original Assignee
Carlsson A Research Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carlsson A Research Ab filed Critical Carlsson A Research Ab
Priority to SE0401465A priority Critical patent/SE0401465D0/sv
Publication of SE0401465D0 publication Critical patent/SE0401465D0/sv
Priority to PCT/EP2005/006152 priority patent/WO2005121092A1/en
Priority to NZ552410A priority patent/NZ552410A/en
Priority to EP05750549A priority patent/EP1765779B1/en
Priority to AU2005251908A priority patent/AU2005251908B2/en
Priority to CN2005800231908A priority patent/CN101076517B/zh
Priority to JP2007526288A priority patent/JP2008501748A/ja
Priority to MXPA06013945A priority patent/MXPA06013945A/es
Priority to CA002569842A priority patent/CA2569842A1/en
Priority to AT05750549T priority patent/ATE449071T1/de
Priority to DK05750549.7T priority patent/DK1765779T3/da
Priority to DE602005017780T priority patent/DE602005017780D1/de
Priority to US11/567,886 priority patent/US7579474B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
SE0401465A 2004-06-08 2004-06-08 New substituted piperdines as modulators of dopamine neurotransmission SE0401465D0 (sv)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SE0401465A SE0401465D0 (sv) 2004-06-08 2004-06-08 New substituted piperdines as modulators of dopamine neurotransmission
DE602005017780T DE602005017780D1 (de) 2004-06-08 2005-06-08 Neue substituierte piperidine als modulatoren der dopamin neurotransmission
AU2005251908A AU2005251908B2 (en) 2004-06-08 2005-06-08 New substituted piperidines as modulators of dopamine neurotransmission
NZ552410A NZ552410A (en) 2004-06-08 2005-06-08 New 4-phenyl-piperidin-4-ol derivatives as modulators of dopamine neurotransmission
EP05750549A EP1765779B1 (en) 2004-06-08 2005-06-08 New substituted piperidines as modulators of dopamine neurotransmission
PCT/EP2005/006152 WO2005121092A1 (en) 2004-06-08 2005-06-08 New substituted piperidines as modulators of dopamine neurotransmission
CN2005800231908A CN101076517B (zh) 2004-06-08 2005-06-08 作为多巴胺神经传递调节剂的取代的哌啶类
JP2007526288A JP2008501748A (ja) 2004-06-08 2005-06-08 ドーパミン神経伝達のモジュレーターとしての新規な置換されたピペリジン
MXPA06013945A MXPA06013945A (es) 2004-06-08 2005-06-08 Piperidinas sustituidas, novedosas, como moduladores de la neurotransmision de dopamina.
CA002569842A CA2569842A1 (en) 2004-06-08 2005-06-08 New substituted piperidines as modulators of dopamine neurotransmission
AT05750549T ATE449071T1 (de) 2004-06-08 2005-06-08 Neue substituierte piperidine als modulatoren der dopamin neurotransmission
DK05750549.7T DK1765779T3 (da) 2004-06-08 2005-06-08 Nye substituerede piperidiner som modulatorer for dopamin-neurotransmission
US11/567,886 US7579474B2 (en) 2004-06-08 2006-12-07 Substituted piperidines as modulators of dopamine neurotransmission

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0401465A SE0401465D0 (sv) 2004-06-08 2004-06-08 New substituted piperdines as modulators of dopamine neurotransmission

Publications (1)

Publication Number Publication Date
SE0401465D0 true SE0401465D0 (sv) 2004-06-08

Family

ID=32653560

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0401465A SE0401465D0 (sv) 2004-06-08 2004-06-08 New substituted piperdines as modulators of dopamine neurotransmission

Country Status (7)

Country Link
US (1) US7579474B2 (sv)
EP (1) EP1765779B1 (sv)
CN (1) CN101076517B (sv)
AU (1) AU2005251908B2 (sv)
CA (1) CA2569842A1 (sv)
SE (1) SE0401465D0 (sv)
WO (1) WO2005121092A1 (sv)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
US7851629B2 (en) 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
MXPA06013944A (es) 2004-06-08 2007-10-08 Neurosearch Sweden Ab Nuevas fenilpiperidinas/piperazinas disustituidas como moduladores de la neurotransmision de dopamina.
AU2005293754B2 (en) 2004-10-13 2011-07-21 Teva Pharmaceuticals International Gmbh Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
MX2009012787A (es) * 2007-06-05 2009-12-15 Nsab Af Neurosearch Sweden Ab Nuevas fenilpirrolidinas disustituidas como moduladores de neurotransmision catecolaminergica cortical.
EP2367786B1 (en) * 2008-11-24 2013-01-09 NSAB, Filial af NeuroSearch Sweden AB, Sverige Novel 1 -alkyl- 3 -hydroxy- 3 -phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
MX2011005034A (es) 2008-11-24 2011-06-16 Nsab Af Neurosearch Sweden Ab Nuevos derivados de 3-fenil-azetidina utiles como moduladores de la neurotransmision catecolaminergica cortical.
TW201026666A (en) * 2008-12-16 2010-07-16 Astrazeneca Ab Quaternary piperidine derivatives and uses thereof
WO2011075470A1 (en) * 2009-12-15 2011-06-23 Astrazeneca Pharmaceuticals Lp Quaternary piperidine compounds and uses thereof
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
JP6177875B2 (ja) 2012-04-04 2017-08-09 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 併用療法のための医薬組成物
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
US11738012B2 (en) 2016-02-24 2023-08-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
DK3503890T3 (da) 2016-08-24 2025-01-27 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til behandling af dystonier
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途
WO2022084999A1 (en) * 2020-10-20 2022-04-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine and analogs for the treatment of anxiety and depression

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE662455A (sv) 1964-04-14
GB1060160A (en) 1964-08-05 1967-03-01 Allen & Hanburys Ltd 4-phenylpiperidine derivatives
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US4048314A (en) * 1974-12-17 1977-09-13 Delmar Chemicals Limited Morpholino containing 4-arylpiperidine derivatives
US4202898A (en) 1978-06-05 1980-05-13 Synthelabo Method of treating anxiety and depression
US4333942A (en) 1979-08-03 1982-06-08 Byk Gulden Lomberg Chemische Fabrik Gmbh Anti-depressant and analgesic 4-phenoxypiperidines
FR2501506A1 (fr) 1981-03-11 1982-09-17 Sanofi Sa Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine
US4415736A (en) 1981-12-28 1983-11-15 E. I. Du Pont De Nemours & Co. Certain tetrahydropyridine intermediates
US4485109A (en) 1982-05-07 1984-11-27 E. I. Du Pont De Nemours And Company 4-Aryl-4-piperidinecarbinols
ATE50987T1 (de) 1982-05-10 1990-03-15 Takeda Chemical Industries Ltd Dihydropyridinderivate, deren herstellung und verwendung.
US4504660A (en) 1982-07-06 1985-03-12 American Home Products Corporation Process for the production of 2,6-diaminobenzonitrile derivatives
HU198454B (en) 1987-12-14 1989-10-30 Richter Gedeon Vegyeszet Process for production of new derivatives of tetrahydrospiridin and medical compositions containing these compounds
FR2639226B1 (fr) 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
JPH05503517A (ja) 1989-12-18 1993-06-10 バージニア・コモンウェルス・ユニバーシティ シグマレセプターリガンド及びその用途
DE69231854T2 (de) 1991-04-17 2001-10-04 Pharmacia & Upjohn Co., Kalamazoo Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten
EP0591426A4 (en) 1991-06-27 1996-08-21 Univ Virginia Commonwealth Sigma receptor ligands and the use thereof
IE914218A1 (en) 1991-09-11 1993-03-24 Mcneilab Inc Novel 4-arylpiperazines and 4-arylpiperidines
GB9119932D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
US5502050A (en) 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
ATE243679T1 (de) 1994-08-18 2003-07-15 Pfizer Neuroprotektive 3-(piperidinyl-1)-chroman-4,7- diol und 1-(4-hyphoxyphenyl)-2-(piperidinyl-1)- alkanolderivate
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
EP0867183B1 (en) 1996-07-22 2004-10-06 Daiichi Suntory Pharma Co., Ltd. Arylpiperidinol and arylpiperidine derivatives and drugs containing the same
US5892041A (en) 1996-08-12 1999-04-06 Neurogen Corporation Fused indolecarboxamides: dopamine receptor subtype specific ligands
DE19637237A1 (de) 1996-09-13 1998-03-19 Merck Patent Gmbh Piperazin-Derivate
EP0846683B1 (en) 1996-12-03 2001-09-19 F. Hoffmann-La Roche Ag 4-Hydroxy-piperidine derivatives
WO1998051668A1 (en) 1997-05-14 1998-11-19 Neurosearch A/S Piperidine derivatives as neurotransmitter re-uptake inhibitors
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
EP1177792A3 (en) 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders
CA2431996A1 (en) 2001-01-23 2002-08-01 Vincent Mancuso Melanocortin receptor agonists
US6815448B2 (en) 2001-05-07 2004-11-09 Wyeth Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists
EP2204363A1 (en) 2004-06-08 2010-07-07 NSAB, Filial af NeuroSearch Sweden AB, Sverige New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
CN101031300A (zh) 2004-10-01 2007-09-05 默克公司 用于治疗或预防糖尿病的作为二肽基肽酶－ⅳ抑制剂的氨基哌啶化合物
AU2005293754B2 (en) 2004-10-13 2011-07-21 Teva Pharmaceuticals International Gmbh Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine
AU2005293755A1 (en) 2004-10-13 2006-04-20 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
WO2007065655A1 (en) 2005-12-07 2007-06-14 Neurosearch Sweden Ab Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission

Also Published As

Publication number Publication date
US20070270467A1 (en) 2007-11-22
EP1765779A1 (en) 2007-03-28
US7579474B2 (en) 2009-08-25
CN101076517B (zh) 2010-12-15
WO2005121092A1 (en) 2005-12-22
CA2569842A1 (en) 2005-12-22
CN101076517A (zh) 2007-11-21
EP1765779B1 (en) 2009-11-18
AU2005251908B2 (en) 2011-03-17
AU2005251908A1 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
SE0401465D0 (sv) New substituted piperdines as modulators of dopamine neurotransmission
IL189298A0 (en) 3.5-disubstituted phenyl-piperidines as modulators of dopamine meurotransmission
EA200702470A1 (ru) Производные пиррола в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
MXPA06014721A (es) Derivados de alquinilo como moduladores de los receptores de glutamato metabotropico.
CY1111733T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
EA200801551A1 (ru) Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
MX2007014405A (es) Novedosos derivados de oxadiazol y su uso como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
EA200700909A1 (ru) Азаиндолкарбоксамиды
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
BRPI0511907A (pt) novos derivados de fenilpiperidinas/piperizinas dissubstituìdos como moduladores da neurotransmissão de dopamina
MX2007014444A (es) Derivados de oxadiazol sustituido como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
DE602007012531D1 (de) Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren
TW200740766A (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands
MXPA06013945A (es) Piperidinas sustituidas, novedosas, como moduladores de la neurotransmision de dopamina.
ATE479691T1 (de) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren
SE0401464D0 (sv) New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
TW200616637A (en) Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
ATE502947T1 (de) 4,5,6,7-tetrahydrothienoä3,2-cüpyridinderivate als h3-modulatoren
HK1110076A (en) Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors